NICE to recommend Roche cancer treatment
pharmafile | June 26, 2020 | News story | Medical Communications | NHS, NICE
NICE are set to recommend Roche’s Rozlytrek (Entrectinib) cancer treatment which will be the second histology drug to be recommended for use on the Cancer Drugs Fund (CDF).
The decision is for patients over 12 years old who suffer from advanced NTRK fusion-positive solid tumours who have no satisfactory treatment options. Patients can access the treatment on the CDF when it has received marketing approval.
Karen Lightning-Jones, Head of Personalised Healthcare and Strategic Partnerships at Roche Products Limited said: “People across England will be among the first in Europe to benefit from a new generation of medicine that targets tumours based on their genetic make-up, rather than where they are in the body.
“We are proud to have worked in partnership with NHSE, NICE and the Accelerated Access Collaborative, to fast-track access. We look forward to the English Genomic Medicine Service being able to operate at full capacity and help identify those patients who may benefit from entrectinib. Our commitment is to ensure that people in the UK live longer and healthier lives, and today’s news shows how we are advancing science to achieve this.”
Between 600 to 700 people have solid tumours with NTRK gene fusions and a proportion of these people will have access to the treatment within the first year of its availability on the CDF.
Professor Peter Johnson, NHS Clinical Director for Cancer, said: “As well as helping cancer patients to continue to get essential care during the coronavirus pandemic, the NHS has been working to bring new treatments onto the frontline of patient care.
“This is the latest deal that the NHS has struck, working together with Roche, to help hundreds of cancer patients every year who will now be able to have this important molecular targeted treatment.”
Conor Kavanagh
Related Content
A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …
The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …
Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …
